EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situationsUniversity of Szeged, Szeged, Hungary.
Office-Based Dermatology Practice, Geel, Belgium.
Radboud University Medical Centre Nijmegen, Nijmegen, Netherlands.
Unidad de Investigación. Fundación Piel Sana AEDV, Madrid, Spain.
University of Verona, Verona, Italy.
University Hospital Copenhagen, Copenhagen, Denmark.
Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
Helsinki University Central Hospital, Helsinki, Finland.
Department of Dermatology, University Hospital of Zürich, Zürich, Switzerland.
International Federation of Psoriasis Associations (IFPA), Germany.
Universitätsklinikum Schleswig-Holstein, Kiel, Germany.
Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
University of Debrecen, Debrecen, Hungary.
Aarhus University Hospital, Aarhus, Denmark.
Municipal Hospital Hietzing, Vienna, Austria.
Department of Dermatology, Medical University of Warsaw, Warsaw, Poland.
Office-Based Dermatology Practice, Mönchengladbach, Germany.
Oslo University Hospital, Oslo, Norway.
International Federation of Psoriasis Associations (IFPA), Germany.
Academic Medical Centre Amsterdam, Amsterdam, Netherlands.
Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Department of Dermatology, Venereology and Allergology, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Show others and affiliations
2021 (English)In: Journal of the European Academy of Dermatology and Venereology, ISSN 0926-9959, E-ISSN 1468-3083, Vol. 35, no 2, p. 281-317Article in journal (Refereed) Published
Abstract [en]
This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The second part of the guideline provides guidance for specific clinical and comorbid situations such as treating psoriasis vulgaris patient with concomitant psoriatic arthritis, concomitant inflammatory bowel disease, a history of malignancies or a history of depression or suicidal ideation. It further holds recommendations for concomitant diabetes, viral hepatitis, disease affecting the heart or the kidneys as well as concomitant neurological disease. Advice on how to screen for tuberculosis and recommendations on how to manage patients with a positive tuberculosis test result are given. It further covers treatment for pregnant women or patients with a wish for a child in the near future. Information on vaccination, immunogenicity and systemic treatment during the COVID-19 pandemic is also provided.
Place, publisher, year, edition, pages
John Wiley & Sons, 2021. Vol. 35, no 2, p. 281-317
National Category
Dermatology and Venereal Diseases
Identifiers
URN: urn:nbn:se:umu:diva-180794DOI: 10.1111/jdv.16926ISI: 000615217300035Scopus ID: 2-s2.0-85100540361OAI: oai:DiVA.org:umu-180794DiVA, id: diva2:1531159
2021-02-252021-02-252023-09-05Bibliographically approved